Barinthus Biotherapeutics plc (BRNS)

Market Cap	25.73M -33.4%
Revenue (ttm)	n/a
Net Income	-66.43M
EPS	-1.64
Shares Out	40.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,628
Open	0.6400
Previous Close	0.6300
Day's Range	0.6300 - 0.6550
52-Week Range	0.5600 - 2.9200
Beta	-0.62
Analysts	Strong Buy
Price Target	4.00 (+534.92%)
Earnings Date	Mar 13, 2026

About BRNS

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2021
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: BRNS
• Website: https://www.barinthusbio.com

Analyst Summary

According to one analyst, the rating for BRNS stock is "Strong Buy" and the 12-month stock price target is $4.0.

Price Target

$4.0

(534.92% upside)

Analyst Consensus: Strong Buy